Sanjay Chanda - 26 Feb 2025 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role: Chief Development Officer
Signature: /s/ Lucy Day, Attorney-in-Fact for Sanjay Chanda
Issuer symbol: ANTX
Transactions as of: 26 Feb 2025
Net transactions value: $0
Form type: 4
Filing time: 28 Feb 2025, 16:27:15 UTC
Previous filing: 07 Jan 2025
Next filing: 07 Jan 2026
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ANTX	Common Stock	Award	$0	+50,250	+168%	$0.000000	80,074	26 Feb 2025	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANTX	Stock Option (right to buy)	Award	$0	+100,500		$0.000000	100,500	26 Feb 2025	Common Stock	100,500	$1.13	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
F2	Includes 20,625 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.
F3	The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.